#1 Clinical Trials Search in Europe

PEGVISOMANT

PEGVISOMANT is a medication used primarily in the treatment of acromegaly, a rare condition characterized by excessive growth hormone (GH) production. Unlike other treatments that reduce GH secretion, PEGVISOMANT works by blocking the growth hormone receptor, preventing GH from exerting its effects on tissues throughout the body. Clinical trials have investigated various aspects of PEGVISOMANT therapy, including its effectiveness in normalizing insulin-like growth factor-1 (IGF-1) levels, its safety profile, dosing considerations, and potential applications beyond acromegaly. This article summarizes the key findings from clinical trials involving PEGVISOMANT to help patients better understand this treatment option.

Table of Contents

What is Pegvisomant?

Pegvisomant (also known by brand names Somavert or B2036-PEG) is a medication used to treat acromegaly, a rare hormonal disorder characterized by excessive growth hormone (GH) production in the body[1]. Acromegaly is usually caused by a benign tumor on the pituitary gland that leads to overproduction of growth hormone, which in turn causes overproduction of another hormone called insulin-like growth factor-1 (IGF-1). Both elevated GH and IGF-1 are responsible for the clinical features of acromegaly.

Pegvisomant was developed as a treatment option for patients with acromegaly who have not responded adequately to surgery, radiation therapy, or other medications such as somatostatin analogs (SSAs) like octreotide or lanreotide[2]. It represents an important advancement in the management of this chronic condition.

How Pegvisomant Works

Unlike other treatments for acromegaly that aim to reduce GH production, pegvisomant works through a different mechanism. It is a growth hormone receptor antagonist that blocks the binding of GH to its receptors in tissues throughout the body[3]. By preventing GH from activating its receptors, pegvisomant inhibits the production of IGF-1, which is the primary mediator of GH’s effects on growth and metabolism.

More specifically, pegvisomant is a genetically engineered analog of human growth hormone that has been modified to bind to GH receptors without activating them. It prevents the necessary conformational change of the GH receptor dimer that would normally trigger the signaling cascade[11]. This effectively blocks the actions of endogenous GH at the tissue level, regardless of how much GH is being produced by the pituitary gland.

It’s important to understand that pegvisomant does not reduce GH secretion from the pituitary tumor; instead, it blocks the hormone’s effects on target tissues. This is why IGF-1 levels, rather than GH levels, are used to monitor treatment efficacy with pegvisomant[3].

Primary Uses of Pegvisomant

The primary use of pegvisomant is for the treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and other medical treatments, or for whom these therapies are not appropriate[4]. Clinical trials have demonstrated that pegvisomant is highly effective in normalizing IGF-1 levels in patients with acromegaly.

Acromegaly is associated with several complications if left untreated, including:

  • Cardiovascular problems: Including hypertrophy (enlargement) of the left ventricle of the heart, which can lead to heart failure[12]
  • Metabolic disturbances: Such as insulin resistance and impaired glucose tolerance, which may progress to diabetes[5]
  • Skeletal changes: Growth of hands, feet, and facial features; joint pain; and potentially an increased risk of osteoporosis[2]
  • Soft tissue swelling: Causing symptoms like excessive sweating, fatigue, and headaches[4]

By normalizing IGF-1 levels, pegvisomant aims to alleviate these symptoms and reduce the risk of long-term complications associated with acromegaly.

How Pegvisomant is Administered

Pegvisomant is administered as a subcutaneous (under the skin) injection, similar to insulin injections[1]. It is available in different strengths, typically 10 mg, 15 mg, or 20 mg per vial, supplied as a lyophilized powder that needs to be reconstituted with sterile water for injection before use[1].

The recommended dosing regimen usually begins with a loading dose, followed by daily maintenance doses. The exact dosage is individualized based on the patient’s response, as measured by IGF-1 levels. Typically, treatment starts with a loading dose of 40-80 mg, followed by daily injections of 10-30 mg, with dose adjustments made in 5-10 mg increments to normalize IGF-1 levels[6].

Patients or their caregivers can be trained to administer the injections at home, which provides convenience for long-term treatment. Recently, clinical trials have also investigated the use of a 30 mg vial to potentially reduce the number of injections needed for higher doses[1].

Efficacy of Pegvisomant

Pegvisomant has demonstrated high efficacy in normalizing IGF-1 levels in patients with acromegaly. Clinical trials have shown that pegvisomant as monotherapy can normalize IGF-1 levels in over 90% of patients, making it one of the most effective medical treatments available for acromegaly[4].

The efficacy of pegvisomant is assessed primarily through monitoring serum IGF-1 levels, which should return to the normal range for age and sex. Clinical improvement in acromegaly symptoms typically follows normalization of IGF-1 levels and may include reduction in excessive sweating, soft tissue swelling, fatigue, joint pain, and headaches[7].

Long-term studies, including post-marketing surveillance conducted in Japan over a 5-year period, have confirmed the sustained efficacy of pegvisomant in controlling acromegaly[4]. This makes it a valuable option for patients who require lifelong management of this chronic condition.

Side Effects and Safety Considerations

Like all medications, pegvisomant may cause side effects. The most commonly reported adverse effects include:

  • Injection site reactions: Redness, pain, or swelling at the injection site[4]
  • Liver function abnormalities: Elevated liver enzymes have been reported in some patients, necessitating regular monitoring of liver function[4]
  • Potential tumor growth: Since pegvisomant blocks GH receptors but does not reduce GH secretion, there is a theoretical concern about pituitary tumor growth. Regular monitoring with MRI is recommended[7]
  • Changes in glucose metabolism: Pegvisomant may improve insulin sensitivity and lower blood glucose levels, which may require adjustment of anti-diabetic medications in patients with diabetes[5]

Safety monitoring during pegvisomant treatment typically includes regular assessment of liver function tests, IGF-1 levels, and periodic MRI of the pituitary to monitor for potential tumor growth[4].

There is also a small risk of developing antibodies against pegvisomant, although this appears to be rare and does not necessarily reduce treatment efficacy[7].

Use in Special Populations

Pegvisomant has been studied in various special populations, including:

Children with Growth Hormone Excess

Clinical trials are investigating the use of pegvisomant in children with gigantism (childhood-onset acromegaly). When growth hormone excess occurs before the complete fusion of growth plates, it leads to pathological tall stature, a condition called gigantism[9]. Preliminary research suggests that pegvisomant may be effective and safe in this population, though dosing must be carefully adjusted based on weight and response[9].

Patients with McCune-Albright Syndrome

Studies have examined the effect of pegvisomant on growth hormone excess in patients with McCune-Albright syndrome, a genetic disorder that can include polyostotic fibrous dysplasia (abnormal bone growth), skin pigmentation, and endocrine problems including GH excess[13]. Pegvisomant may help reduce the effects of growth hormone excess in these patients.

Patients with Insulin Resistance

Interestingly, pegvisomant is also being studied for its potential benefits in conditions of severe insulin resistance, such as lipodystrophy and insulin receptor mutations. By blocking GH action, pegvisomant may reduce lipolysis (fat breakdown) and improve insulin sensitivity[5]. This represents a novel application of the drug beyond its approved use in acromegaly.

Combination Therapy

While pegvisomant is effective as monotherapy, it is sometimes used in combination with other medications for acromegaly, particularly somatostatin analogs (SSAs) such as octreotide or lanreotide. Combination therapy may offer several advantages:

  • Improved efficacy in patients who have an incomplete response to SSAs alone[7]
  • Potential for dose reduction of either medication, which may reduce side effects and costs[6]
  • Complementary mechanisms of action: SSAs reduce GH secretion, while pegvisomant blocks GH action at the receptor level[7]

Studies have shown that combination therapy with a somatostatin analog and weekly pegvisomant can normalize IGF-1 levels in up to 95% of patients who were inadequately controlled on SSAs alone[6]. This approach may be particularly useful for patients with partial resistance to SSA therapy.

More recently, studies have investigated the combination of pasireotide (a newer somatostatin analog) with pegvisomant, which may offer additional benefits for some patients[14].

Research Applications

Beyond its clinical use in acromegaly, pegvisomant has proven valuable as a research tool to better understand GH physiology and metabolism. Some interesting research applications include:

Studies on Metabolism and Insulin Sensitivity

Researchers have used pegvisomant to investigate the role of GH in regulating metabolism, particularly during fasting states. By blocking GH action with pegvisomant, scientists can better understand how GH contributes to maintaining blood glucose levels and mobilizing fat stores during periods of food restriction[8].

Bone Microarchitecture Research

Pegvisomant has been used to study the effects of GH/IGF-1 normalization on bone density and microarchitecture in acromegaly patients. This research helps clarify how excess GH affects bone health and fracture risk[2].

Cancer Research

Some studies have explored the potential of combining pegvisomant with other therapies in cancer treatment, particularly for cancers that may be influenced by the GH/IGF-1 axis[10]. This represents an innovative application of GH receptor blockade beyond endocrine disorders.

Effects on Quality of Life

Acromegaly can significantly impair quality of life due to physical changes, pain, fatigue, and psychological distress. Treatment with pegvisomant has been shown to improve quality of life in patients with acromegaly, as measured by acromegaly-specific quality of life questionnaires (AcroQoL)[7].

Improvements are often seen in both physical symptoms (such as excessive sweating, fatigue, and joint pain) and psychological aspects (including appearance concerns and social functioning)[7]. Some studies suggest that even patients who have “biochemically controlled” acromegaly on somatostatin analogs may experience further quality of life improvements when switching to or adding pegvisomant[7].

The convenience of self-administration and the high rate of biochemical control contribute to patient satisfaction with pegvisomant treatment. However, the need for daily injections and the high cost of the medication remain considerations that may affect long-term adherence and access to therapy[7].

Aspect Details
Mechanism of Action PEGVISOMANT is a genetically engineered growth hormone receptor antagonist that blocks the binding of growth hormone (GH) to receptors in tissues throughout the body, preventing GH-stimulated production of insulin-like growth factor-1 (IGF-1).
Primary Use Treatment of acromegaly, particularly in patients who have had an inadequate response to surgery, radiation therapy, and/or other medical treatments.
Efficacy Measures Primary efficacy endpoint in most trials is normalization of IGF-1 levels. Secondary measures include improvements in clinical symptoms, quality of life, and other biomarkers related to GH excess.
Dosing Administered via subcutaneous injection. Dosing regimens range from daily injections (10-30 mg) to weekly administration (40-120 mg), with dose adjustments based on IGF-1 levels.
Combination Therapy Often studied in combination with somatostatin analogs (octreotide, lanreotide, pasireotide) or dopamine agonists to achieve better IGF-1 control with potentially lower doses of each medication.
Safety Profile Common adverse events include injection site reactions, liver enzyme elevations, headaches, and arthralgia. Regular monitoring of liver function, tumor size, and glucose metabolism is recommended.
Special Populations Studied in pediatric patients with gigantism and growth hormone excess. Also investigated in conditions with insulin resistance, including partial lipodystrophy and severe insulin resistance syndromes.
Metabolic Effects May improve insulin sensitivity and glucose metabolism in some patients, potentially beneficial for acromegaly patients with diabetes or impaired glucose tolerance.
Skeletal Effects Studies have examined effects on bone mineral density, bone microarchitecture, and fracture risk in acromegaly patients, as GH and IGF-1 play important roles in bone metabolism.
Cardiovascular Effects Some research has evaluated the impact on cardiac structure and function, including left ventricular mass and ejection fraction, which can be adversely affected by untreated acromegaly.

FAQ

  • What is PEGVISOMANT and how does it work? PEGVISOMANT (also known by the brand name Somavert) is a genetically engineered growth hormone receptor antagonist. Unlike other acromegaly treatments that reduce growth hormone secretion from the pituitary gland, PEGVISOMANT works by blocking the binding of growth hormone to its receptors throughout the body. This prevents growth hormone from stimulating the production of insulin-like growth factor-1 (IGF-1), which is responsible for many of the symptoms and complications of acromegaly.
  • How effective is PEGVISOMANT in treating acromegaly? Clinical trials have shown PEGVISOMANT to be highly effective in normalizing IGF-1 levels in patients with acromegaly. When used as monotherapy, PEGVISOMANT can normalize IGF-1 levels in approximately 95% of patients. It is particularly valuable for patients who don't respond adequately to other treatments like surgery, radiation therapy, or somatostatin analogs. Studies have also shown improvements in clinical symptoms such as excessive sweating, fatigue, and soft tissue swelling when IGF-1 levels are controlled.
  • What are the common dosing regimens for PEGVISOMANT? PEGVISOMANT is typically administered as a subcutaneous (under the skin) injection. Clinical trials have studied various dosing schedules, including daily injections (10-30 mg per day) and weekly regimens (40-120 mg per week). Some studies have explored combination therapy with somatostatin analogs, which may allow for reduced dosing of both medications. The dose is usually adjusted based on IGF-1 levels, with the goal of maintaining IGF-1 within the normal range for the patient's age and sex.
  • What are the potential side effects of PEGVISOMANT? In clinical trials, PEGVISOMANT was generally well-tolerated. The most commonly reported side effects include injection site reactions (redness, pain, or swelling at the injection site), liver enzyme elevations, and headaches. Some patients may experience changes in blood glucose levels, which is important for patients with diabetes to monitor. Less common but more serious side effects can include liver injury and potential growth of the pituitary tumor, so regular monitoring is recommended during treatment.
  • Can PEGVISOMANT be used for conditions other than acromegaly? While PEGVISOMANT is primarily approved for acromegaly, clinical trials have investigated its potential use in other conditions. Some studies have explored its effects in patients with severe insulin resistance, partial lipodystrophy, and certain growth disorders in children. Research has also examined its potential to improve insulin sensitivity and glucose metabolism in various patient populations. However, these uses are still investigational, and PEGVISOMANT is currently only approved for the treatment of acromegaly.

Ongoing Clinical Trials on PEGVISOMANT

  • Study on the Effects of Pegvisomant and Somatropin on Liver Fat Metabolism in Patients with Acromegaly and Healthy Individuals

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

Glossary

  • Acromegaly: A rare hormonal disorder that results when the pituitary gland produces too much growth hormone (GH) during adulthood. It most commonly results from a benign tumor on the pituitary gland and leads to gradual enlargement of body tissues, particularly the hands, feet, and face.
  • Bioavailability: The proportion of a drug or substance that enters the circulation when introduced into the body and is able to have an active effect. Studies comparing different formulations of PEGVISOMANT have assessed relative bioavailability.
  • Bone Microarchitecture: The detailed structural arrangement of bone tissue at the microscopic level, which contributes to bone strength and quality. This can be measured using high-resolution imaging techniques like HR-pQCT.
  • Combination Therapy: Treatment approach that uses multiple medications simultaneously, such as PEGVISOMANT together with somatostatin analogs, to achieve better control of acromegaly than either medication alone.
  • Dopamine Agonist: A class of medications (e.g., cabergoline) that activate dopamine receptors and can be used to treat certain pituitary tumors, sometimes used in combination with other acromegaly treatments.
  • Gigantism: A rare condition characterized by excessive growth, particularly in height, due to excess growth hormone production during childhood or adolescence before the growth plates have closed.
  • Growth Hormone (GH): A peptide hormone produced by the pituitary gland that stimulates growth, cell reproduction, and regeneration. Excessive GH production leads to acromegaly or gigantism.
  • Growth Hormone Receptor (GHR): A protein on the surface of cells that binds to growth hormone, initiating cellular responses. PEGVISOMANT works by blocking this receptor, preventing growth hormone from binding.
  • Hyperinsulinemic Euglycemic Clamp: A technique used to measure insulin sensitivity, where insulin is infused to maintain a constant elevated insulin level while glucose is simultaneously infused to maintain normal blood glucose levels.
  • IGF-1 (Insulin-like Growth Factor-1): A hormone produced primarily by the liver in response to growth hormone stimulation. Blood levels of IGF-1 are used to monitor acromegaly disease activity and treatment effectiveness.
  • Insulin Resistance: A condition where cells fail to respond normally to insulin, leading to higher blood glucose levels. Growth hormone excess can contribute to insulin resistance.
  • Lanreotide: A somatostatin analog used to treat acromegaly by reducing growth hormone secretion from the pituitary gland, sometimes used in combination with PEGVISOMANT.
  • Lipodystrophy: A disorder characterized by abnormal distribution or loss of fat tissue, which can lead to severe metabolic complications including insulin resistance.
  • McCune-Albright Syndrome: A genetic disorder characterized by abnormal bone development, skin pigmentation, and endocrine problems, including growth hormone excess in some patients.
  • Octreotide: A somatostatin analog medication (brand name Sandostatin) used to treat acromegaly by reducing growth hormone secretion from the pituitary gland.
  • Pasireotide: A newer somatostatin analog (brand name Signifor) that binds to multiple somatostatin receptor subtypes and may be effective in patients who don't respond to traditional somatostatin analogs.
  • Pituitary MRI: Magnetic resonance imaging of the pituitary gland, used to visualize pituitary tumors and monitor potential changes in tumor size during treatment.
  • Quality of Life (QoL): A measure of an individual's general well-being, including physical health, mental health, and social functioning. Several clinical trials have assessed how PEGVISOMANT affects quality of life in acromegaly patients.
  • Somatostatin Analog (SSA): A class of medications that mimic the action of somatostatin, a natural hormone that inhibits growth hormone release. Examples include octreotide and lanreotide, commonly used in acromegaly treatment.
  • Subcutaneous Injection: An injection administered into the fatty tissue layer between the skin and muscle. PEGVISOMANT is typically given as a subcutaneous injection.
  • Trabecular Bone Score: A measurement derived from dual-energy X-ray absorptiometry (DXA) that provides an indirect assessment of bone microarchitecture and bone quality.
  • Z-score: A statistical measurement that expresses how many standard deviations a value is from the mean of a reference population, often used to report IGF-1 levels relative to age- and sex-matched normal values.

References

  1. https://clinicaltrials.gov/study/NCT01181973
  2. https://clinicaltrials.gov/study/NCT03225040
  3. https://clinicaltrials.gov/study/NCT01261000
  4. https://clinicaltrials.gov/study/NCT00658879
  5. https://clinicaltrials.gov/study/NCT05470504
  6. https://clinicaltrials.gov/study/NCT01538966
  7. https://clinicaltrials.gov/study/NCT02952885
  8. https://clinicaltrials.gov/study/NCT02500095
  9. https://clinicaltrials.gov/study/NCT03882034
  10. https://clinicaltrials.gov/study/NCT00976508
  11. https://clinicaltrials.gov/study/NCT00512473
  12. https://clinicaltrials.gov/study/NCT00552851
  13. https://clinicaltrials.gov/study/NCT00017927
  14. https://clinicaltrials.gov/study/NCT02668172